{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:26:28Z","timestamp":1790349988301,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010905","name":"Illumina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010905","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Klinbeforsk"},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008388","name":"Radiumhospitalets Forskningsstifltelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"InCyte","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen due to recent advancements in cancer diagnostics including access to high-throughput sequencing of tumour tissue. Targeted therapies interfering with cancer specific pathways have been developed and approved for subgroups of patients. These drugs might just as well be efficient in other diagnostic subgroups, not investigated in pharma-led clinical studies, but their potential use on new indications is never explored due to limited number of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this national, investigator-initiated, prospective, open-label, non-randomized combined basket- and umbrella-trial, patients are enrolled in multiple parallel cohorts. Each cohort is defined by the patient\u2019s tumour type, molecular profile of the tumour, and study drug. Treatment outcome in each cohort is monitored by using a Simon two-stage-like \u2018admissible\u2019 monitoring plan to identify evidence of clinical activity.<\/jats:p>\n                <jats:p>All drugs available in IMPRESS-Norway have regulatory approval and are funded by pharmaceutical companies. Molecular diagnostics are funded by the public health care system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Precision oncology means to stratify treatment based on specific patient characteristics and the molecular profile of the tumor. Use of targeted drugs is currently restricted to specific biomarker-defined subgroups of patients according to their market authorization. However, other cancer patients might also benefit of treatment with these drugs if the same biomarker is present. The emerging technologies in molecular diagnostics are now being implemented in Norway and it is publicly reimbursed, thus more cancer patients will have a more comprehensive genomic profiling of their tumour. Patients with actionable genomic alterations in their tumour may have the possibility to try precision cancer drugs through IMPRESS-Norway, if standard treatment is no longer an option, and the drugs are available in the study. This might benefit some patients. In addition, it is a good example of a public\u2013private collaboration to establish a national infrastructure for precision oncology.<\/jats:p>\n                <jats:p><jats:italic>Trial registrations<\/jats:italic> EudraCT: 2020-004414-35, registered 02\/19\/2021; ClinicalTrial.gov: NCT04817956, registered 03\/26\/2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-022-03432-5","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T13:03:34Z","timestamp":1652533414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway"],"prefix":"10.1186","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct04817956","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5520-0275","authenticated-orcid":false,"given":"\u00c5slaug","family":"Helland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hege G.","family":"Russnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro Live","family":"Fagereng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al-Shibli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Bj\u00f8rge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egil","family":"Blix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodil","family":"Bjerkehagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigmund","family":"Brabrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte Gr\u00f8nlie","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Dalhaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Dietzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"D\u00f8nnem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Enerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5smund","family":"Flobak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sverre","family":"Fluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rnar","family":"Gilje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Tore","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Henning","family":"Gr\u00f8nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Gr\u00f8n\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tormod","family":"Guren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Hamre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5se","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir Olav","family":"Hjortland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eivind","family":"Hovig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Hovland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Charlotte","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Amund","family":"Kyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedda","family":"von der Lippe Gythfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnhild","family":"Lothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-\u00c5smund","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Meza-Zepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Cheng","family":"Munthe-Kaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav Toai Duc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitt","family":"Niehusmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Nilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Puco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Hansen","family":"Ree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonje B\u00f8yum","family":"Riste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Semb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli Sihn Samdal","family":"Steinskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stensvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Suhrke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind","family":"Tenn\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir E.","family":"Tj\u00f8nnfjord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv Jorunn","family":"Vassbotn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Aas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Aaseb\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"Tasken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigbj\u00f8rn","family":"Smeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,14]]},"reference":[{"issue":"15","key":"3432_CR1","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2012.46.8934","volume":"31","author":"LA Garraway","year":"2013","unstructured":"Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013;31(15):1806\u201314.","journal-title":"J Clin Oncol"},{"issue":"7484","key":"3432_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence MS, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495\u2013501.","journal-title":"Nature"},{"issue":"35","key":"3432_CR3","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1200\/JCO.2009.27.4944","volume":"28","author":"LE Macconaill","year":"2010","unstructured":"Macconaill LE, Garraway LA. Clinical implications of the cancer genome. J Clin Oncol. 2010;28(35):5219\u201328.","journal-title":"J Clin Oncol"},{"issue":"R1","key":"3432_CR4","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1093\/hmg\/ddu234","volume":"23","author":"A Rafii","year":"2014","unstructured":"Rafii A, et al. Where cancer genomics should go next: a clinician\u2019s perspective. Hum Mol Genet. 2014;23(R1):R69-75.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"3432_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1470-2045(13)70611-9","volume":"15","author":"F Andre","year":"2014","unstructured":"Andre F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01\/UNICANCER). Lancet Oncol. 2014;15(3):267\u201374.","journal-title":"Lancet Oncol"},{"issue":"33","key":"3432_CR6","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","volume":"28","author":"DD Von Hoff","year":"2010","unstructured":"Von Hoff DD, et al. Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877\u201383.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3432_CR7","doi-asserted-by":"publisher","first-page":"djv253","DOI":"10.1093\/jnci\/djv253","volume":"107","author":"DL Jardim","year":"2015","unstructured":"Jardim DL, et al. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst. 2015;107(11):djv253.","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"3432_CR8","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Le Tourneau","year":"2015","unstructured":"Le Tourneau C, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324\u201334.","journal-title":"Lancet Oncol"},{"issue":"8","key":"3432_CR9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","volume":"4","author":"J Marquart","year":"2018","unstructured":"Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 2018;4(8):1093\u20138.","journal-title":"JAMA Oncol"},{"issue":"5","key":"3432_CR10","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","volume":"25","author":"J Rodon","year":"2019","unstructured":"Rodon J, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25(5):751\u20138.","journal-title":"Nat Med"},{"issue":"7","key":"3432_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/0284186X.2020.1742377","volume":"59","author":"AH Ree","year":"2020","unstructured":"Ree AH, et al. Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer\u2014the MetAction study. Acta Oncol. 2020;59(7):733\u201340.","journal-title":"Acta Oncol"},{"issue":"33","key":"3432_CR12","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1200\/JCO.19.03010","volume":"38","author":"KT Flaherty","year":"2020","unstructured":"Flaherty KT, et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020;38(33):3883\u201394.","journal-title":"J Clin Oncol"},{"key":"3432_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00036","author":"A Johnson","year":"2017","unstructured":"Johnson A, et al. Clinical use of precision oncology decision support. JCO Precis Oncol. 2017. https:\/\/doi.org\/10.1200\/PO.17.00036.","journal-title":"JCO Precis Oncol"},{"issue":"7793","key":"3432_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1913-9","volume":"578","author":"Y Li","year":"2020","unstructured":"Li Y, et al. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578(7793):112\u201321.","journal-title":"Nature"},{"issue":"1","key":"3432_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310.","journal-title":"Control Clin Trials"},{"issue":"4","key":"3432_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/sim.1600","volume":"23","author":"SH Jung","year":"2004","unstructured":"Jung SH, et al. Admissible two-stage designs for phase II cancer clinical trials. Stat Med. 2004;23(4):561\u20139.","journal-title":"Stat Med"},{"issue":"7776","key":"3432_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","volume":"574","author":"DL van der Velden","year":"2019","unstructured":"van der Velden DL, et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574(7776):127\u201331.","journal-title":"Nature"},{"issue":"2","key":"3432_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000516","volume":"4","author":"J van de Haar","year":"2019","unstructured":"van de Haar J, Hoes L, Voest E. Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine. ESMO Open. 2019;4(2): e000516.","journal-title":"ESMO Open"},{"key":"3432_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00002","author":"AM Tsimberidou","year":"2017","unstructured":"Tsimberidou AM, et al. Initiative for molecular profiling and advanced cancer therapy (IMPACT): an MD Anderson precision medicine study. JCO Precis Oncol. 2017. https:\/\/doi.org\/10.1200\/PO.17.00002.","journal-title":"JCO Precis Oncol"},{"key":"3432_CR20","unstructured":"NKI. European collaboration. The Netherlands Cancer Institute, Press Release, Nov 26, 2021: \u201cDutch-Nordic Alliance for Precision Cancer Medicine launched\u201d. 2021. https:\/\/www.nki.nl\/news-events\/news\/dutch-nordic-alliance-for-precision-cancer-medicine-launched\/."},{"key":"3432_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00122","author":"PK Mangat","year":"2018","unstructured":"Mangat PK, et al. Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2018. https:\/\/doi.org\/10.1200\/PO.18.00122.","journal-title":"JCO Precis Oncol."},{"issue":"2","key":"3432_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"3432_CR23","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352.","journal-title":"Lancet Oncol"},{"issue":"12","key":"3432_CR24","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"27","key":"3432_CR25","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3432_CR26","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963\u201372.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3432_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419\u201323.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"3432_CR28","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","volume":"30","author":"D Mandelker","year":"2019","unstructured":"Mandelker D, et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol. 2019;30(8):1221\u201331.","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1186\/s12967-022-03518-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000}}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03432-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T11:10:37Z","timestamp":1657883437000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03432-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,14]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3432"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03432-5","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12967-022-03518-0","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,14]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12967-022-03518-0","URL":"https:\/\/doi.org\/10.1186\/s12967-022-03518-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is approved by the regional ethics committee (REK-S\u00f8r-\u00d8st, REK # 200764). Patients have received written and oral information about the study and have signed an informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Roche, Novartis, Eli Lilly, Incyte, and Illumina have seen and approved this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study is supported by several pharmaceutical companies (Roche, Novartis, Eli Lilly, Incyte) in addition to Foundation Medicine and Illumina. None of the authors receive reimbursement or salaries for this study from companies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}